RxDoctor Payments Data

Brittany Denaro, DO

Ophthalmology · Cookeville, TNNPI 1356702773

Payments from drug & device makers

What this record shows

The money is spread across several categories — education (51.7%), food and beverage and travel and lodging — rather than concentrated in one kind of arrangement. 17 manufacturers reported payments, led by Carl Zeiss Meditec, Inc. at 51.7% of the total. Reporting peaked in 2023 at $5,254 and has fallen 85.3% since, to $775 in 2025.

$7,976in general payments, 2019–2025

Across 109 payments — averaging $73.17 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Carl Zeiss Meditec, Inc.$4K
  • Alcon$2K
  • Carl Zeiss Meditec USA, Inc.$998
  • Rxsight Inc$451
  • AbbVie$254
  • Glaukos Corporation$113
  • plus $501 from 11 others

What the payments were for

  • Travel & lodging$1,11014%
  • Food & beverage$2,70434%
  • Education$4,12552%
  • Gifts$360%

General payments by program year

20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$7,976 in reported general payments places this provider in the 85th percentile of 323 ophthalmology providers in Tennessee.

See all ophthalmology providers in Tennessee

Medicare billing

Part B allowed, 2024
$277,631
Medicare patients
749
Services billed
2,312

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
XiidraLifitegrast15$15,626
RocklatanNetarsudil Mesylat/Latanoprost14$5,167
LumiganBimatoprost11$3,870
Bromfenac Sodium38$3,602
Prednisolone Acetate72$2,198
ValacyclovirValacyclovir Hcl38$1,986
Latanoprost195$1,946
Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol18$1,737
Timolol Maleate163$1,670
Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat63$1,037
Ketorolac Tromethamine41$976
Brimonidine Tartrate58$498
MoxifloxacinMoxifloxacin Hcl11$208
ErythromycinErythromycin Base14$154

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieLumigan$254$3,87011 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 323 ophthalmology providers in Tennessee.

Other ophthalmology in Cookeville

See the full list for Tennessee

Where these figures come from

Is this you, or does something look wrong? →